Published in Br J Pharmacol on March 05, 2007
The role of exercise and PGC1alpha in inflammation and chronic disease. Nature (2008) 5.31
A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell (2009) 4.60
Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A (2008) 4.50
Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol (2014) 3.46
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis (2009) 2.49
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci (2010) 1.96
Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain (2008) 1.92
Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci (2008) 1.85
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Will the real multiple sclerosis please stand up? Nat Rev Neurosci (2012) 1.61
Animal models of Parkinson's disease progression. Acta Neuropathol (2008) 1.49
CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol (2009) 1.43
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One (2011) 1.40
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation (2008) 1.40
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Occupational factors and risk of Parkinson's disease: A population-based case-control study. Am J Ind Med (2010) 1.26
The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One (2010) 1.23
A review of experimental evidence linking neurotoxic organophosphorus compounds and inflammation. Neurotoxicology (2012) 1.22
Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm (Vienna) (2010) 1.22
MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci (2013) 1.21
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J Biol Chem (2010) 1.20
Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol (2009) 1.20
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther (2008) 1.19
Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol (2008) 1.15
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm (2013) 1.12
Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells. Int J Med Sci (2008) 1.10
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation (2008) 1.06
Complexity of dopamine metabolism. Cell Commun Signal (2013) 1.06
Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A (2012) 1.05
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation (2014) 1.05
Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics (2008) 1.04
The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. Nutr J (2008) 1.04
Regulation of microglia effector functions by tumor necrosis factor signaling. Glia (2011) 1.04
Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini Rev Med Chem (2009) 1.03
Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-κB pathways. Acta Pharmacol Sin (2013) 1.00
Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol (2012) 1.00
The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis. J Neural Transm (Vienna) (2013) 0.99
Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. J Neurochem (2009) 0.99
Oxidative stress in genetic mouse models of Parkinson's disease. Oxid Med Cell Longev (2012) 0.98
PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides (2008) 0.98
Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology (2009) 0.98
CD 4+ T cells in the pathobiology of neurodegenerative disorders. J Neuroimmunol (2009) 0.97
Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One (2011) 0.97
Parkinson's disease and systemic inflammation. Parkinsons Dis (2011) 0.96
Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis. Epilepsia (2012) 0.95
Design and synthesis of manganese porphyrins with tailored lipophilicity: investigation of redox properties and superoxide dismutase activity. Bioorg Med Chem (2007) 0.95
Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci (2013) 0.95
Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol (2015) 0.94
San-Huang-Xie-Xin-Tang Protects against Activated Microglia- and 6-OHDA-Induced Toxicity in Neuronal SH-SY5Y Cells. Evid Based Complement Alternat Med (2011) 0.92
Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantia nigra. Exp Mol Med (2010) 0.92
Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proc Natl Acad Sci U S A (2012) 0.91
Proteolytic activation of proapoptotic kinase protein kinase Cδ by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation (2012) 0.91
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience (2008) 0.91
Neural stem cell niches in health and diseases. Curr Pharm Des (2012) 0.91
Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis (2011) 0.91
Metabolic syndrome: an important risk factor for Parkinson's disease. Oxid Med Cell Longev (2014) 0.90
Inhalation of environmental stressors & chronic inflammation: autoimmunity and neurodegeneration. Mutat Res (2008) 0.89
Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neuroinflammation (2010) 0.89
Evidence of inflammatory system involvement in Parkinson's disease. Biomed Res Int (2014) 0.89
Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators Inflamm (2015) 0.89
Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol (2010) 0.88
Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J Neurol (2012) 0.88
Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures. Oxid Med Cell Longev (2013) 0.87
Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice. Mol Neurodegener (2015) 0.87
The p53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf. J Immunol (2013) 0.87
PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices. Exp Neurobiol (2013) 0.87
Neuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives for the natural combination of both in krill oil. Nutrients (2014) 0.86
Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm (Vienna) (2011) 0.86
Potential mechanisms of progranulin-deficient FTLD. J Mol Neurosci (2011) 0.86
Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. PLoS One (2016) 0.85
Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J Neuroinflammation (2011) 0.85
The role of the JAK2-STAT3 pathway in pro-inflammatory responses of EMF-stimulated N9 microglial cells. J Neuroinflammation (2010) 0.85
Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J Mol Cell Biol (2014) 0.85
An association study between Heme oxygenase-1 genetic variants and Parkinson's disease. Front Cell Neurosci (2014) 0.84
Association of fibrinogen with Parkinson disease in elderly Japanese-American men: a prospective study. Neuroepidemiology (2009) 0.84
Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease. J Neuroinflammation (2007) 0.83
Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4. J Neuroinflammation (2014) 0.83
Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. Exp Neurol (2007) 0.83
Age and duration of inflammatory environment differentially affect the neuroimmune response and catecholaminergic neurons in the midbrain and brainstem. Neurobiol Aging (2013) 0.83
Parkinson's disease. Subcell Biochem (2012) 0.82
Markers of inflammation in prevalent and incident Parkinson's disease in the Cardiovascular Health Study. Parkinsonism Relat Disord (2011) 0.82
6-Shogaol, an active compound of ginger, protects dopaminergic neurons in Parkinson's disease models via anti-neuroinflammation. Acta Pharmacol Sin (2013) 0.82
Estrogen-related and other disease diagnoses preceding Parkinson's disease. Clin Epidemiol (2010) 0.81
Prenatal LPS increases inflammation in the substantia nigra of Gdnf heterozygous mice. Brain Pathol (2010) 0.81
Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties. J Neurodegener Dis (2015) 0.81
Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease. Acta Neuropathol Commun (2014) 0.81
Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflammation (2013) 0.80
Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation. J Neuroinflammation (2012) 0.80
Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease. Br J Pharmacol (2012) 0.80
A phenotypic model recapitulating the neuropathology of Parkinson's disease. Brain Behav (2013) 0.79
Lipopolysaccharide sensitized male and female juvenile brains to ionizing radiation. Cell Death Dis (2013) 0.79
Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease. Neurotox Res (2013) 0.79
Eyes as gateways for environmental light to the substantia nigra: relevance in Parkinson's disease. ScientificWorldJournal (2014) 0.79
The biochemistry of apoptosis. Nature (2000) 18.91
Microglia: a sensor for pathological events in the CNS. Trends Neurosci (1996) 12.00
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell (1987) 9.41
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature (1996) 6.75
Parkinson's disease. First of two parts. N Engl J Med (1998) 5.90
Oxidative stress and neurodegeneration: where are we now? J Neurochem (2006) 5.44
Programmed cell death induced by ceramide. Science (1993) 5.43
Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol (2005) 4.96
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med (1999) 4.88
Immune function of microglia. Glia (2001) 4.59
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys (1992) 4.12
The role of inflammation in CNS injury and disease. Br J Pharmacol (2006) 3.96
Cytokines and acute neurodegeneration. Nat Rev Neurosci (2001) 3.70
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol (1999) 3.63
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
Apoptosis and caspases in neurodegenerative diseases. N Engl J Med (2003) 3.40
Mitochondrial disease. Lancet (2006) 3.38
Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging (2001) 3.36
Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci (2006) 3.20
Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem (2002) 3.14
Phagocytes and oxidative stress. Am J Med (2000) 3.00
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem (2003) 2.92
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 2.91
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci (2000) 2.75
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
Microglia in health and disease. J Neurosci Res (2005) 2.74
Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev (1999) 2.57
Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A (1989) 2.56
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord (2004) 2.41
Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol (1999) 2.31
Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol (1988) 2.28
Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci (2003) 2.24
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci (2002) 2.17
Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci (1993) 2.16
FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell (1996) 2.15
Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol (2003) 2.14
Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord (1998) 2.12
In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience (1997) 2.07
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions. J Cell Biol (2000) 2.04
Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J (2004) 2.00
Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res (2004) 1.97
Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol (2002) 1.90
Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci (2002) 1.87
Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta (1999) 1.87
Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci (2003) 1.87
Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol (2005) 1.82
Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J (2002) 1.79
Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol (1978) 1.79
Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem (2000) 1.78
Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today (2000) 1.77
Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci (2002) 1.75
Role of complement in neurodegeneration and neuroinflammation. Mol Immunol (2006) 1.73
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Cytotoxic and genotoxic potential of dopamine. J Neurosci Res (1999) 1.70
The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis (2000) 1.70
In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord (2002) 1.68
Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci (2000) 1.66
Environment, mitochondria, and Parkinson's disease. Neuroscientist (2002) 1.63
The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol (1999) 1.59
Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci (2003) 1.58
Control of glial immune function by neurons. Glia (2001) 1.58
Does prepregnancy bacterial vaginosis increase a mother's risk of having a preterm infant with cerebral palsy? Dev Med Child Neurol (1997) 1.58
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci (1999) 1.58
Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci (2002) 1.57
Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol (2006) 1.57
Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem (1998) 1.52
Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci (2001) 1.52
Parkinsonism: onset, progression, and mortality. 1967. Neurology (1998) 1.52
Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem (2006) 1.49
Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol (1998) 1.47
Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp (1999) 1.46
Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol (1998) 1.45
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun (2006) 1.45
Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J (2003) 1.43
Circulating cell wall components derived from gram-negative, not gram-positive, bacteria cause a profound induction of the gene-encoding Toll-like receptor 2 in the CNS. J Neurochem (2001) 1.41
An inflammatory review of Parkinson's disease. Prog Neurobiol (2002) 1.39
Genetics of parkinsonism. Mov Disord (2002) 1.38
Glial cell influence on the human blood-brain barrier. Glia (2001) 1.36
The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal (2005) 1.34
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci (2005) 1.33
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
N-acetyl-cysteine suppresses amniotic fluid and placenta inflammatory cytokine responses to lipopolysaccharide in rats. Am J Obstet Gynecol (2006) 1.32
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse (2001) 1.31
Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther (2003) 1.30
Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration (1996) 1.30
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci (2003) 1.30
Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res (2001) 1.29
Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem (1995) 1.29
The dual effect of the particulate and organic components of diesel exhaust particles on the alteration of pulmonary immune/inflammatory responses and metabolic enzymes. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev (2002) 1.28